San Antonio researcher receives top American diabetes award
June 12, 2008
Studies of insulin resistance, development of frontline therapies shape his legacy.
June 12, 2008
Studies of insulin resistance, development of frontline therapies shape his legacy.
June 12, 2008
In a research study of hundreds of patients facing the prospect of developing type 2 diabetes, the oral drug pioglitazone (brand name: Actos®) reduced the rate of conversion to the disease by 81 percent in the active therapy group compared to those taking a placebo, the study leader, Ralph A. DeFronzo, M.D., reported June 9 during the 68th Scientific Sessions of the American Diabetes Association in San Francisco.
May 14, 2008
A three-year research study by The University of Texas Health Science Center at San Antonio seeks volunteers ages 18-30 and 65 and older to compare levels of a protein called NFkB (NF-kappa-B).
January 24, 2008
World-renowned diabetes researcher Ralph A. DeFronzo, M.D., is the 2008 Presidential Distinguished Scholar at The University of Texas Health Science Center at San Antonio.
January 24, 2008
World-renowned diabetes researcher Ralph A. DeFronzo, M.D., is the 2008 Presidential Distinguished Scholar at The University of Texas Health Science Center at San Antonio.
November 12, 2007
The University of Texas Health Science Center at San Antonio, in a joint effort with the American Diabetes Association, the Juvenile Diabetes Research Foundation and the University Health System, will participate in a ceremony recognizing Wednesday, Nov. 14, as World Diabetes Day.